Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial

Fransecky L, Fiedler W, Röllig C, Sauer T, Raffel S, Alsdorf W, Heberling L, Steer B, Huber K, Versteegen T, Spory L, Deckbar D, Reiser L, Bendig S, Bastian L, Bozzetti C, Beder T, Neumann M, Brüggemann M, Gökbuget N, Baldus C.